Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	19	138	180	239	586	834
Market Cap Growth	-74.50%	-23.47%	-24.70%	-59.17%	-29.79%	561.07%
Enterprise Value	43	26	44	62	372	458
Last Close Price	0.08	0.54	0.79	1.46	3.75	5.39
PS Ratio	0.31	0.77	2.99	8.81	95.26	210.78
PB Ratio	-	11.63	4.56	2.92	2.84	2.44
P/TBV Ratio	-	17.30	4.60	2.94	2.86	2.46
P/FCF Ratio	-	-	-	-	271.82	-
P/OCF Ratio	-	-	-	-	54.60	-
EV/Sales Ratio	0.67	0.15	0.73	2.28	60.44	115.73
EV/FCF Ratio	-	-	-	-	172.44	-
Debt / Equity Ratio	-0.69	6.26	0.64	0.28	0.12	0.07
Debt / FCF Ratio	-	-	-	-	11.82	-
Asset Turnover	0.29	0.67	0.20	0.07	0.01	0.01
Inventory Turnover	24.04	34.25	97.02	126.15	78.45	51.66
Quick Ratio	0.69	2.60	2.66	3.76	6.45	9.96
Current Ratio	1.52	2.92	2.85	3.96	6.64	10.19
Return on Equity (ROE)	-1341.10%	-275.75%	-187.61%	-114.97%	-57.78%	-55.97%
Return on Assets (ROA)	-40.86%	-12.39%	-26.71%	-25.67%	-22.03%	-26.36%
Return on Capital (ROIC)	-152.32%	-43.44%	-96.27%	-60.93%	-34.01%	-32.44%
Earnings Yield	-819.01%	-51.37%	-63.22%	-69.17%	-26.99%	-15.59%
FCF Yield	-924.72%	-53.75%	-80.82%	-71.60%	0.37%	-6.70%
Buyback Yield / Dilution	-8.53%	-25.48%	-24.73%	-3.47%	-9.37%	-35.72%

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q